This presentation contains forward-looking statements, including statements regarding the benefits of NERLYNX® (neratinib) and neratinib, the commercialization of NERLYNX, the potential indications of our drug candidates and the development of our drug candidates, including, but not limited to, the anticipated timing for the commencement and completion of various clinical trials and announcement of data relative to these trials. All statements other than historical facts are forward–looking statements and are based on our current expectations, forecasts and assumptions. Forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in our Annual Report on Form 10-K for the year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and any subsequent documents we file with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.
Puma’s Pharmacy and Distributor Network

Specialty Pharmacy Network
- Acaria Health
- Accredo
- CVS
- Onco360
- Diplomat
- Biologics

Specialty Distributer / GPO Network
- McKesson
- ASD / Oncology Supply
- Cardinal Health

Hub Services

Patients

Sites of Care
- Academic Hospitals
- Community Hospitals
- Private Practice
- Other (VA, DoD)
Net Product Sales grew 79% from Q4 to Q1

**NERLYNX® Net Sales in $ M**

- **Q3 2017**: $6.1
- **Q4 2017**: $20.1
- **Q1 2018**: $36.0

+ 79%
Net Sales since FDA approval is approximately $76.3 M
Specialty Pharmacy Enrollments – Through April 30, 2018

2,413 SP Enrollments

- 138 (5.7%) Free Drug
- 159 (6.6%) In Process
- 2,116 (87.6%) Commercial Patients Dispensed
  - 1,614 (76.3%) Active
  - 502 (23.7%) Discontinued

- Specialty Pharmacies account for approximately 88% of total business
• Could include duplicate RX’s sent to multiple specialty pharmacies
• Enrollment numbers reported for historical months may be slightly different from previous statements due to SP data updates
NRx: New Rx Dispensed
TRx: Total Rx Dispensed
Time to First Fill (or shipment) by Specialty Pharmacy

72% of patients receive their first shipment within 15 days of an SP in our network receiving their RX
New and Total NERLYNX® Prescribers in SP Channel

QUARTERLY NEW AND CUMULATIVE NERLYNX SP WRITERS

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Quarterly New SP Writers</th>
<th>Cumulative SP Writers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3-2017</td>
<td>385</td>
<td>385</td>
</tr>
<tr>
<td>Q4-2017</td>
<td>529</td>
<td>914</td>
</tr>
<tr>
<td>Q1-2018</td>
<td>502</td>
<td>1416</td>
</tr>
</tbody>
</table>

* Prescriber numbers reported for historical months may be slightly different from previous statements due to SP data restatements.
Increasing reach to more targeted prescribers

QUARTERLY TARGET HCP REACH

Q3-2017: 25%
Q4-2017: 51%
Q1-2018: 57%

* Call numbers reported for historical months may be slightly different from previous statements due to Veeva data updates
Puma Biotechnology
Earnings Call
Commercial Update

May 9, 2018